BR112017010561A2 - administração intranasal - Google Patents

administração intranasal

Info

Publication number
BR112017010561A2
BR112017010561A2 BR112017010561A BR112017010561A BR112017010561A2 BR 112017010561 A2 BR112017010561 A2 BR 112017010561A2 BR 112017010561 A BR112017010561 A BR 112017010561A BR 112017010561 A BR112017010561 A BR 112017010561A BR 112017010561 A2 BR112017010561 A2 BR 112017010561A2
Authority
BR
Brazil
Prior art keywords
oxytocin
antagonists
nozzle
providing
intranasal administration
Prior art date
Application number
BR112017010561A
Other languages
English (en)
Portuguese (pt)
Inventor
David Sheldrake Colin
S Quintana Daniel
T Smerud Knut
T Westlye Lars
A Andreassen Ole
Gisle Djupesland Per
A Mahmoud Ramy
Original Assignee
Optinose As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optinose As filed Critical Optinose As
Publication of BR112017010561A2 publication Critical patent/BR112017010561A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00—Dilators with or without means for introducing media, e.g. remedies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BR112017010561A 2014-11-19 2015-11-19 administração intranasal BR112017010561A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081742P 2014-11-19 2014-11-19
PCT/EP2015/077162 WO2016079267A1 (en) 2014-11-19 2015-11-19 Intranasal administration

Publications (1)

Publication Number Publication Date
BR112017010561A2 true BR112017010561A2 (pt) 2017-12-26

Family

ID=54695714

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017010561A BR112017010561A2 (pt) 2014-11-19 2015-11-19 administração intranasal
BR112017010522-5A BR112017010522B1 (pt) 2014-11-19 2015-11-19 Peça de nariz para a distribuição de substância para uma cavidade nasal de um indivíduo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017010522-5A BR112017010522B1 (pt) 2014-11-19 2015-11-19 Peça de nariz para a distribuição de substância para uma cavidade nasal de um indivíduo

Country Status (19)

Country Link
US (6) US10940277B2 (https=)
EP (3) EP3220989B1 (https=)
JP (2) JP6937690B2 (https=)
KR (2) KR20170086599A (https=)
CN (3) CN107106792B (https=)
AU (2) AU2015348301B2 (https=)
BR (2) BR112017010561A2 (https=)
CA (2) CA2966797C (https=)
DK (2) DK3220988T3 (https=)
ES (3) ES2949052T3 (https=)
HK (1) HK1244729A1 (https=)
IL (2) IL251936B (https=)
MX (2) MX383241B (https=)
MY (1) MY188242A (https=)
PL (1) PL3220989T3 (https=)
RU (2) RU2017114950A (https=)
SG (2) SG11201703794TA (https=)
WO (2) WO2016079271A1 (https=)
ZA (1) ZA201704149B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0604444D0 (en) * 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
WO2012123819A1 (en) 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
DK3281664T3 (da) 2012-02-24 2021-01-25 Optinose As Nasale indgivelsesindretninger
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
MY188242A (en) 2014-11-19 2021-11-24 Optinose As Intranasal administration
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
KR102947035B1 (ko) 2018-04-12 2026-04-02 로켓 사이언스 헬스 코퍼레이션 비강 내 약물 전달 기구
KR102148613B1 (ko) * 2019-01-28 2020-10-14 닉스 주식회사 이산화탄소를 이용한 수면 유도시스템
CN110188836B (zh) * 2019-06-21 2021-06-11 西安交通大学 一种基于变分自编码器的脑功能网络分类方法
EP4013369B1 (en) * 2019-08-14 2025-01-15 Haleon CH SARL Nozzle for a container for intranasal administration
CA3152988A1 (en) 2019-08-29 2021-03-04 New York University Oxytocin compositions for treatment of tinnitus
WO2021118433A1 (en) 2019-12-09 2021-06-17 Aak Ab (Publ) Wax compositions for use in candles and methods of preparing wax compositions
US20220161000A1 (en) * 2020-11-24 2022-05-26 Medtronic, Inc. Multi-durometer attachment device for chronic fixation
CN112999499A (zh) * 2021-04-20 2021-06-22 苏州新劢德医疗器械科技有限公司 流体分配设备
CN121288169A (zh) * 2021-04-20 2026-01-09 苏州新劢德医疗器械科技有限公司 一种流体分配设备
CN114306207A (zh) * 2021-12-30 2022-04-12 电子科技大学 一种以棒棒糖为载体的口腔给药方法
US20230285278A1 (en) * 2022-03-06 2023-09-14 Optinose, Inc. Methods for treating chronic rhinosinusitis
WO2025118074A1 (en) * 2023-12-04 2025-06-12 Rocket Science Health Corp. Olfactory delivery of therapeutic peptides
WO2025174892A1 (en) * 2024-02-13 2025-08-21 Breathewave Technologies Inc. Personalized-fit nasal dilator

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605436A (en) 1898-06-07 Inhaler
US642748A (en) 1899-02-23 1900-02-06 Arthur Manners Inhaler.
US658436A (en) 1900-05-28 1900-09-25 Hans Hennerich Groth Insufflator.
US746749A (en) 1903-03-18 1903-12-15 George E Seidel Nasal medicator.
US794641A (en) 1905-03-06 1905-07-11 Alfred H Ramey Inhaler.
US902832A (en) 1907-09-20 1908-11-03 Edward F Philbrook Inhaler.
KR100390480B1 (ko) 1995-01-23 2003-10-04 디렉트-할러 아/에스 흡입기
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
JP3320288B2 (ja) 1995-11-15 2002-09-03 株式会社ユニシアジェックス 鼻腔用投薬器
US5797392C1 (en) 1996-01-22 2001-01-09 Direct Haler As Inhaler
PL189855B1 (pl) 1997-05-27 2005-09-30 Direct Haler As Urządzenie do podawania sproszkowanej substancji aktywnej
GB9719775D0 (en) * 1997-09-18 1997-11-19 Glaxo Group Ltd Device
FR2771296B1 (fr) 1997-11-25 2000-03-10 Sofab Embout nasal avec fermeture d'extremite
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
GB0015309D0 (en) 2000-06-21 2000-08-16 Djupesland Per G Apparatus
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
GB0300008D0 (en) 2003-01-02 2003-02-05 Optinose As Delivery devices
GB2400565B (en) 2003-04-17 2005-03-02 Bespak Plc Nasal drug delivery
GB0311570D0 (en) 2003-05-20 2003-06-25 Optinose As Delivery device and method
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
GB0320171D0 (en) 2003-08-28 2003-10-01 Optinose As Delivery devices
GB0405477D0 (en) 2004-03-11 2004-04-21 Glaxo Group Ltd A fluid dispensing device
USD530815S1 (en) 2004-03-19 2006-10-24 Optinose As Nasal delivery device
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
JP4765526B2 (ja) 2005-10-04 2011-09-07 オムロンヘルスケア株式会社 吸入器および吸入器用マウスピース
AU2006335994A1 (en) 2006-01-19 2007-07-26 Optinose As Nasal administration
EP1988953B1 (en) 2006-02-14 2017-07-19 Optinose AS Delivery device
GB0602980D0 (en) 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB0604444D0 (en) 2006-03-06 2006-04-12 Optinose As Nasal devices
GB0605799D0 (en) 2006-03-23 2006-05-03 Optinose As Nasal delivery devices
GB2437488A (en) 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
JP2008062974A (ja) 2006-09-07 2008-03-21 Mitani Valve Co Ltd 内容物放出用容器ならびに、この内容物放出用容器を備えたポンプ式製品およびエアゾール式製品
GB0623731D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery device
GB0623728D0 (en) 2006-11-28 2007-01-10 Optinose As Delivery devices
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
US20100199984A1 (en) 2007-04-02 2010-08-12 Abbott Laboratories Breath actuated nasal pump
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
US8342173B2 (en) 2007-07-19 2013-01-01 Silver Eagle Labs Inc. Nasal dilator with cushion layer and variable spring rate
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
CN101980738A (zh) 2008-02-07 2011-02-23 华盛顿大学 圆周气雾设备
WO2009102976A2 (en) 2008-02-15 2009-08-20 Timothy Sean Immel Aerosol therapy device with high frequency delivery
US20110318345A1 (en) 2008-09-15 2011-12-29 Optinose As Nasal delivery
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
GB201020638D0 (en) 2010-12-06 2011-01-19 Liconsa Laboratorios Sa Inhalator
WO2012123819A1 (en) * 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
RU112044U1 (ru) 2011-08-25 2012-01-10 Наиль Минрахманович Нуртдинов Тренажер-ингалятор
CA2865355C (en) 2012-02-24 2021-02-16 Optinose As Nasal delivery devices
IN2014DN07611A (https=) 2012-02-24 2015-05-15 Optinose As
DK3281664T3 (da) 2012-02-24 2021-01-25 Optinose As Nasale indgivelsesindretninger
PL2978482T3 (pl) 2013-03-26 2022-10-03 Optinose As Podawanie donosowe
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
USD761951S1 (en) 2013-05-23 2016-07-19 Optinose As Nosepiece unit
USD723156S1 (en) 2013-05-23 2015-02-24 Optinose As Nasal delivery device
USD725769S1 (en) 2013-05-23 2015-03-31 Optinose As Nasal delivery device
MY188242A (en) 2014-11-19 2021-11-24 Optinose As Intranasal administration
US20220296825A1 (en) 2018-10-04 2022-09-22 Optinose As Exhalation delivery system for and method of treating sinus disease

Also Published As

Publication number Publication date
US10940277B2 (en) 2021-03-09
AU2015348297A1 (en) 2017-05-25
EP3733235B1 (en) 2023-06-14
US11052204B2 (en) 2021-07-06
RU2017114950A (ru) 2018-12-19
BR112017010522B1 (pt) 2022-08-02
US20230372647A1 (en) 2023-11-23
JP6937690B2 (ja) 2021-09-22
HK1244729A1 (zh) 2018-08-17
RU2714168C2 (ru) 2020-02-12
CN107106792A (zh) 2017-08-29
ES2906984T3 (es) 2022-04-21
HK1244728A1 (en) 2018-08-17
CA2966802C (en) 2022-11-15
US20250114543A1 (en) 2025-04-10
US11730904B2 (en) 2023-08-22
ES2949052T3 (es) 2023-09-25
EP3220988A1 (en) 2017-09-27
US20160331916A1 (en) 2016-11-17
BR112017010522A2 (pt) 2017-12-26
CN111921046B (zh) 2022-07-22
MX383241B (es) 2025-03-13
US20210275761A1 (en) 2021-09-09
JP2017538477A (ja) 2017-12-28
EP3733235A1 (en) 2020-11-04
CA2966797C (en) 2023-06-27
SG11201703792XA (en) 2017-06-29
EP3220988B1 (en) 2022-01-12
IL251936B (en) 2020-07-30
PL3220989T3 (pl) 2021-03-22
IL251935A0 (en) 2017-06-29
CN106999684A (zh) 2017-08-01
US11707586B2 (en) 2023-07-25
CN111921046A (zh) 2020-11-13
RU2017114951A (ru) 2018-12-19
SG11201703794TA (en) 2017-06-29
DK3220988T3 (da) 2022-02-14
MY188242A (en) 2021-11-24
DK3220989T3 (da) 2020-08-24
WO2016079267A1 (en) 2016-05-26
CN106999684B (zh) 2021-03-09
WO2016079271A1 (en) 2016-05-26
CA2966797A1 (en) 2016-05-26
EP3220989B1 (en) 2020-06-24
JP6990583B2 (ja) 2022-01-12
US20160310683A1 (en) 2016-10-27
KR20170086599A (ko) 2017-07-26
RU2017114951A3 (https=) 2019-04-16
US20210322690A1 (en) 2021-10-21
MX2017006268A (es) 2017-08-14
CA2966802A1 (en) 2016-05-26
AU2015348301A1 (en) 2017-05-25
MX2017006265A (es) 2017-08-14
EP3733235C0 (en) 2023-06-14
CN107106792B (zh) 2020-08-18
ZA201704149B (en) 2019-12-18
KR20170085121A (ko) 2017-07-21
ES2813442T3 (es) 2021-03-23
IL251936A0 (en) 2017-06-29
JP2017538478A (ja) 2017-12-28
EP3220989A1 (en) 2017-09-27
AU2015348301B2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
BR112017010561A2 (pt) administração intranasal
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
UA122868C2 (uk) Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування
MX2016014581A (es) Composiciones de compuestos que modulan nmdar.
MX365383B (es) Medicamentos de administracion nasal y metodos para su uso.
MX2016012766A (es) Sistema y metodo para suministro de gas terapeutico a pacientes en necesidad del mismo usando la medicion de flujo de gas de circuito de respiracion (bcg) mejorada.
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
ZA202503350B (en) Semaglutide in medical therapy
EA201892327A1 (ru) Ингаляционные и назальные бензодиазепины
MX2021001786A (es) Antagonistas de integrina.
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
PH12021550671A1 (en) Prodrugs of cgrp antagonists
PH12016501072A1 (en) Composition for oral delivery of bioactive agents
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
BR112016002544A2 (pt) aparelho dosador
ZA201906153B (en) Pharmaceutical compositions for combination therapy

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]